CK Biotech

CK Biotech is a South Korean biotechnology company specializing in the development of first-in-class therapeutics targeting the Wnt/beta-catenin signaling pathway. Founded by Professor Choi Kang-yell of Yonsei University, the company focuses on disrupting the interaction between CXXC5 and Dishevelled (DVL) to promote tissue regeneration. Their primary research areas include androgenetic alopecia (hair loss), chronic wound healing, and metabolic diseases such as obesity and NASH. The company's lead programs involve peptide-based and small-molecule activators of the Wnt pathway that have demonstrated significant efficacy in stimulating hair follicle development and skin repair in preclinical models. By targeting the negative regulator CXXC5, CK Biotech aims to provide regenerative solutions for conditions with high unmet medical needs.